Targeting metabolism for lupus therapy

Science Translational Medicine

Volumn 7, Issue 274, 2015, Pages

  Mehta, Manan M ^a   Chandel, Navdeep S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DEOXYGLUCOSE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METFORMIN; PREDNISONE;

ARTHRALGIA; ARTHRITIS; CD4+ T LYMPHOCYTE; DERMATITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; METABOLIC REGULATION; NEPHRITIS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; METABOLISM;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84929492218     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa6731     Document Type: Review

References (10)

1. Y. Yin, S.-C. Choi, Z. Xu, D. J. Perry, H. Seay, B. P. Croker, E. S. Sobel, T. M. Brusko, L. Morel, Normalization of CD4+ T cell metabolism reverses lupus. Sci. Transl. Med. 7, 274ra18 (2015).
2. E. L. Pearce, M. C. Poff enberger, C. H. Chang, R. G. Jones, Fueling immunity: Insights into metabolism and lymphocyte function. Science 342, 1242454 (2013).
3. L. A. Sena, S. Li, A. Jairaman, M. Prakriya, T. Ezponda, D. A. Hildeman, C. R. Wang, P. T. Schumacker, J. D. Licht, H. Perlman, P. J. Bryce, N. S. Chandel, Mitochondria are required for antigen-specifi c T cell activation through reactive oxygen species signaling. Immunity 38, 225-236 (2013).
4. R. Wang, C. P. Dillon, L. Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L. L. McCormick, P. Fitzgerald, H. Chi, J. Munger, D. R. Green, The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011).
5. M. Foretz, B. Guigas, L. Bertrand, M. Pollak, B. Viollet, Metformin: From mechanisms of action to therapies. Cell Metab. 20, 953-966 (2014).
6. A. N. Macintyre, V. A. Gerriets, A. G. Nichols, R. D. Michalek, M. C. Rudolph, D. Deoliveira, S. M. Anderson, E. D. Abel, B. J. Chen, L. P. Hale, J. C. Rathmell, The glucose transporter Glut1 is selectively essential for CD4 T cell activation and eff ector function. Cell Metab. 20, 61-72 (2014).
7. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka, S. Soberanes, L. B. Sullivan, E. Anso, A. Glasauer, E. Dufour, G. M. Mutlu, G. S. Budigner, N. S. Chandel, Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).
8. A. Martin-Montalvo, E. M. Mercken, S. J. Mitchell, H. H. Palacios, P. L. Mote, M. Scheibye-Knudsen, A. P. Gomes, T. M. Ward, R. K. Minor, M. J. Blouin, M. Schwab, M. Pollak, Y. Zhang, Y. Yu, K. G. Becker, V. A. Bohr, D. K. Ingram, D. A. Sinclair, N. S. Wolf, S. R. Spindler, M. Bernier, R. de Cabo, Metformin improves healthspan and lifespan in mice. Nat. Commun. 4, 2192 (2013).
9. A. Singhal, L. Jie, P. Kumar, G. S. Hong, M. K. Leow, B. Paleja, L. Tsenova, N. Kurepina, J. Chen, F. Zolezzi, B. Kreiswirth, M. Poidinger, C. Chee, G. Kaplan, Y. T. Wang, G. De Libero, Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159 (2014).
10. A. K. Madiraju, D. M. Erion, Y. Rahimi, X. M. Zhang, D. T. Braddock, R. A. Albright, B. J. Prigaro, J. L. Wood, S. Bhanot, M. J. MacDonald, M. J. Jurczak, J. P. Camporez, H. Y. Lee, G. W. Cline, V. T. Samuel, R. G. Kibbey, G. I. Shulman, Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546 (2014).